ASH 2020 | The phase III trial Apollo supports administering daratumumab subcutaneously instead of intravenously in relapsed or refractory myeloma patientsConferences, MyelomaDecember 5, 2020
ASH 2020 | Visit our poster on myeloma patient information needs and preferences at ASH 2020!Conferences, MPE, MyelomaDecember 5, 2020
Register now for MPE’s webinar on Evidence-Based Patient AdvocacyMPE, Patient evidenceOctober 19, 2020
The FDA approves belantamab mafodotin for relapsed or refractory myelomaAccess, MyelomaAugust 6, 2020
